Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 12/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4732906 | 0.86 | SLC6A7 (0.53) | SLC6A7SLC6A3CNR1CNR2MAP4K4 | |
| SCHEMBL4734023 | 0.84 | SLC6A7 (0.51) | SLC6A7SLC6A3CNR1CNR2MAP4K4 | |
| SCHEMBL5102741 | 0.84 | SLC6A7 (0.51) | SLC6A7SLC6A3CNR1CNR2TP53 | |
| SCHEMBL4731854 | 0.84 | SLC6A7 (0.51) | SLC6A7SLC6A3CNR1CNR2MAP4K4 | |
| SCHEMBL5090495 | 0.81 | SCD (0.53) | SLC6A7SLC6A3CNR1CNR2MAP4K4 | |
| SCHEMBL14175664 | 0.81 | SLC6A7 (0.58) | SLC6A7SLC6A3CNR1CNR2MAP4K4 | |
| SCHEMBL4732695 | 0.80 | CNR1 (0.41) | CNR1CNR2TP53KDM4EMAPT | |
| SCHEMBL4732580 | 0.80 | SLC6A7 (0.49) | SLC6A7SLC6A3CNR1CNR2TP53 | |
| SCHEMBL4730640 | 0.79 | ALDH1A1 (0.44) | SLC6A7CNR1CNR2TP53KDM4E | |
| SCHEMBL4730349 | 0.77 | SLC6A7 (0.43) | SLC6A7SLC6A3CNR1CNR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139598-A1 | Amine-linked Multicyclic Compounds and Methods of Their Use | LEXICON PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | claimed |
| WO-2008058064-A1 | AMINE-LINKED MULTICYCLIC COMPOUNDS AS INHIBITORS OF THE PROLINE TRANSPORTER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| US-20080139598-A1 | Amine-linked Multicyclic Compounds and Methods of Their Use | LEXICON PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008058064-A1 | AMINE-LINKED MULTICYCLIC COMPOUNDS AS INHIBITORS OF THE PROLINE TRANSPORTER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139598-A1 | Amine-linked Multicyclic Compounds and Methods of Their Use | MAOB, HNMT, MAOA | SLC6A7 607/4885SLC6A3 263/4885CNR1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.